Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging blinded results showing infection improvement and a positive safety profile. The trial, conducted in Indonesia with 90 patients enrolled, continues recruiting and dosing while awaiting the committee's recommendations, which could lead to regulatory submission if outcomes remain favorable.
Recce Pharmaceuticals' Phase 3 diabetic foot infection trial progress is presented here alongside Pluang's health sector market snapshot as of Oct 20, 2026 05:21 WIB: Among 150 priced US health stocks, 81 rose and 67 fell. Hinge Health Inc. leads with a price of USD 103.96 and a 1-day gain of +4.84%, contrasting with Recursion Pharmaceuticals at USD 3.63 and a similar 1-day gain of +4.76%, despite a Pluang order activity skewed 72% Sell. Relay Therapeutics trades at USD 17.06 with a +4.79% change and a notably longer typical hold time of 10 days compared to Hinge Health's 5 days and Recursion's 21 days.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Flipkart, owned by Walmart, is launching a food delivery service in India to compete against dominant players Zomato and Swiggy. The company is currently testing the service internally in Bengaluru with plans for a public launch by October and expans...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
